Published • loading... • Updated
Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026
- Antengene presented clinical results for ATG-022 and ATG-037 at the 2026 European Society for Medical Oncology Annual Congress.
- In the ATG-022 1.8 mg/kg cohort, 30 evaluable patients had a 46.7% overall response rate and an 86.7% disease control rate.
- Median overall survival for the ATG-022 cohort had not been reached after 17.4 months of follow-up.
- Among 23 evaluable patients, ATG-037 combined with pembrolizumab produced a 21.7% overall response rate and a 95.6% disease control rate.
Insights by Ground AI
36 Articles
36 Articles
Appalachian News-Express+34 Reposted by 34 other sources
Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026
SHANGHAI and HONG KONG, Oct. 25, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies,…
Coverage Details
Total News Sources36
Leaning Left3Leaning Right2Center26Last UpdatedBias Distribution84% Center
Bias Distribution
- 84% of the sources are Center
84% Center
C 84%
Factuality
To view factuality data please Upgrade to Premium
